25 January 2012 - US Cleveland BioLabs Inc (NASDAQ:CBLI) on Tuesday announced management changes aimed at speeding up progress towards strategic goals after CEO Michael Fonstein resigned from the post.

Fonstein will continue to serve as president of the company driving efforts to advance the CBLB502 programme towards regulatory licensure as a countermeasure for Acute Radiation Syndrome, supporting recently formed joint ventures and leading promising business development opportunities.

At the same time, current COO Yakov Kogan will take the CEO role on an interim basis to head and co-ordinate strategic and operational activities.

C Neil Lyons, who is currently chief financial officer, will take additional responsibility as head of investor and public relations, while Andrei Gudkov will continue serving as chief scientific officer.

CBLB502, a bio-engineered derivative of a microbial protein, is being developed as an agent for both mitigation of radiation injury and cancer treatment.